Huang J, Chan WC, Ngai CH, Lok V, Zhang L, Lucero-Prisno DE 3rd, et al. Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. Cancers (Basel). 2022;14(9):2230. https://doi.org/10.3390/cancers14092230.

Article  CAS  PubMed  Google Scholar 

Arora T, Mullangi S, Lekkala MR. Ovarian cancer. StatPearls. 2023.

Maiorano MFP, Maiorano BA, Biancofiore A, Cormio G, Maiello E. Niraparib and advanced ovarian cancer: a beacon in the non-BRCA mutated setting. Pharmaceuticals (Basel). 2023;16(9):1261. https://doi.org/10.3390/ph16091261.

Article  CAS  PubMed  Google Scholar 

Jiang Y, Zhao J, Zhang L, Tian S, Yang T, Wang L, et al. Evaluation of the efficacy and safety of PARP inhibitors in advanced-stage epithelial ovarian cancer. Front Oncol. 2020;10:954. https://doi.org/10.3389/fonc.2020.00954.

Article  PubMed  PubMed Central  Google Scholar 

Marchetti C, Fagotti A, Tombolini V, Scambia G, De Felice F. The role of secondary cytoreductive surgery in recurrent ovarian cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2021;28(6):3258–63. https://doi.org/10.1245/s10434-020-09226-7.

Article  PubMed  Google Scholar 

Otsuka I, Matsuura T. Screening and prevention for high-grade serous carcinoma of the ovary based on carcinogenesis-fallopian tube- and ovarian-derived tumors and incessant retrograde bleeding. Diagnostics (Basel). 2020;10(2):120. https://doi.org/10.3390/diagnostics10020120.

Article  CAS  PubMed  Google Scholar 

Atallah GA, Kampan NC, Chew KT, Mohd Mokhtar N, Md Zin RR, Shafiee MNB, Abd Aziz NHB. Predicting prognosis and platinum resistance in ovarian cancer: role of immunohistochemistry biomarkers. Int J Mol Sci. 2023;24(3):1973. https://doi.org/10.3390/ijms24031973.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672–705. https://doi.org/10.1093/annonc/mdz062.

Article  CAS  PubMed  Google Scholar 

Lee YJ, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT. Rethinking radical surgery in interval debulking surgery for advanced-stage ovarian cancer patients undergoing neoadjuvant chemotherapy. J Clin Med. 2020;9(4):1235. https://doi.org/10.3390/jcm9041235.

Article  PubMed  PubMed Central  Google Scholar 

Pejovic T, Fitch K, Mills G. Ovarian cancer recurrence: is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments? Cancer Drug Resist. 2022;5(2):451–8. https://doi.org/10.0517/cdr.2021.138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Malley DM, Krivak TC, Kabil N, Munley J, Moore KN. PARP inhibitors in ovarian cancer: a review. Target Oncol. 2023;18(4):471–503. https://doi.org/10.1007/s11523-023-00970-w.

Article  PubMed  PubMed Central  Google Scholar 

Miller RE, El-Shakankery KH, Lee JY. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies. J Gynecol Oncol. 2022;33(3): e44. https://doi.org/10.3802/jgo.2022.33.e44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu XH, Zhu JQ, Yin RT, Yang JX, Liu JH, Wang J, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2021;32(4):512–21. https://doi.org/10.1016/j.annonc.2020.12.018.

Article  CAS  PubMed  Google Scholar 

Mirza MR, González-Martín A, Graybill WS, O’Malley DM, Gaba L, Stephanie Yap OW, et al. Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Cancer. 2023;129(12):1846–55. https://doi.org/10.1002/cncr.34706.

Article  CAS  PubMed  Google Scholar 

Musacchio L, Palluzzi E, Di Napoli M, Lauria R, Ferrandina G, Angioli R, et al. Real world data of niraparib in platinum sensitive relapsed ovarian cancer: a multicenter experience of the MITO group. Gynecol Oncol. 2024;184:24–30. https://doi.org/10.1016/j.ygyno.2024.01.022.

Article  CAS  PubMed  Google Scholar 

Cueva JF, Palacio I, Churruca C, Herrero A, Pardo B, Constenla M, et al. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: a GEICO retrospective observational study within the Spanish expanded-access programme. Eur J Cancer. 2023;182:3–14. https://doi.org/10.1016/j.ejca.2022.12.023.

Article  CAS  PubMed  Google Scholar 

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–64. https://doi.org/10.1056/NEJMoa1611310.

Article  CAS  PubMed  Google Scholar 

Yubero A, Barquín A, Estévez P, Pajares B, Sánchez L, Reche P, et al. Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain—a GEICO study. BMC Cancer. 2022;22(1):1150. https://doi.org/10.1186/s12885-022-10191-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paulet L, Trecourt A, Leary A, Peron J, Descotes F, Devouassoux-Shisheboran M, et al. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. Eur J Cancer. 2022;166:87–99. https://doi.org/10.1016/j.ejca.2022.01.037.

Article  CAS  PubMed  Google Scholar 

Vilming B, Fallås Dahl J, Bentzen AG, Ingebrigtsen VA, Berge Nilsen E, Vistad I, et al. Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer. Int J Gynecol Cancer. 2023;33(12):1898–905. https://doi.org/10.1136/ijgc-2023-004484.

Article  PubMed  PubMed Central  Google Scholar 

González-Martín A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–402. https://doi.org/10.1056/NEJMoa1910962.

Article  PubMed  Google Scholar 

Graybill W, Pardo B, Omalley DM, Vergote I, Monk B, Auranen A, et al. Predictors of long-term progression-free survival (PFS) in niraparib-treated patients (pts) from the PRIMA/ENGOT-OV26/GOG-3012 study. J Clin Oncol. 2023;41(16_suppl):5589.

Article  Google Scholar 

González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, et al. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023;189:112908. https://doi.org/10.1016/j.ejca.2023.04.024.

Article  CAS  PubMed  Google Scholar 

Li N, Zhu J, Yin R, Wang J, Pan L, Kong B, et al. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2023;9(9):1230–7. https://doi.org/10.1001/jamaoncol.2023.2283.

Article  PubMed  PubMed Central  Google Scholar 

Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Barceló IB, et al. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecol Oncol. 2020;159(2):442–8. https://doi.org/10.1016/j.ygyno.2020.09.006.

Article  CAS  PubMed  Google Scholar 

Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. J Clin Oncol. 2019;37(32):2968–73. https://doi.org/10.1200/jco.18.02238.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Monk BJ, González-Martin A, Buckley L, Matulonis UA, Rimel BJ, Wu X, et al. Safety and management of niraparib monotherapy in ovarian cancer clinical trials. Int J Gynecol Cancer. 2023;33(6):971–81. https://doi.org/10.1136/ijgc-2022-004079.

Article  PubMed  PubMed Central  Google Scholar